Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
111. |
ECCT/21/06/01 | ACTIV-2/A5401 ACTIV-2/A5401 "Adaptive Platform Treatment Trial for Outpatients with COVID-19" (Adapt Out COVID)_ |
Principal Investigator(s) 1. Charles Meja Kwobah Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
View |
112. |
ECCT/21/05/05 | The “EMPATHY” Trial A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19. |
Principal Investigator(s) 1. DR LUCAS OTIENO TINA 2. Dr. Bernhards Ragama Ogutu 3. Dr Deborah Chepngeno Langat 4. Dr Videlis Nduba Nduba 5. Dr Janet Oyieko Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. Kenyatta University Teaching Referral and Research Hospital (KUTRRH) (Nairobi City county) 3. Kenya Medical Research Institute/US Army Medical Research Directorate-Kenya-Kericho (Kericho county) 4. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 5. KEMRI-USAMRD-A, Kisumu Field Station (Kisumu county) |
View |
113. |
ECCT/21/05/03 | Adapt Out COVID Adaptive Platform Treatment trial for Outpatients with COVID-19 |
Principal Investigator(s) 1. Kawango Agot Site(s) in Kenya 1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county) 2. KEMRI WALTER REED (Kericho county) 3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 4. Kenya Medical Research Institute (Kisumu county) |
View |
114. |
ECCT/21/03/02 | PB-SAM Pancreatic Enzymes and Bile Acids: A Non-Antibiotic approach to Treat Intestinal Dysbiosis in Acutely Ill Severely Malnourished Children. |
Principal Investigator(s) 1. Robert Bandsma Site(s) in Kenya 1. Kilifi County Hospital (Kilifi county) 2. Coast General Hospital (Mombasa county) 3. Mbagathi Hospital (Nairobi City county) 4. Migori County Hospital (Migori county) |
View |
115. |
ECCT/21/03/01 | Recombinant COVID-19 vaccine A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older |
Principal Investigator(s) 1. Walter Jaoko Jaoko Site(s) in Kenya KAVI-institute of Clinical Research |
View |